HistologiX
UK-based contract research organisation providing GLP/GCP-compliant tissue-based biomarker analysis and histopathology services. Core activities include histology and specialised staining, immunohistochemistry and immunofluorescence assay development, whole-slide scanning and quantitative image analysis, tissue cross-reactivity studies for biologics, and support for preclinical toxicology and clinical trials. Holds human tissue sourcing licences and offers pathology review by board-certified pathologists.
Industries
Nr. of Employees
small (1-50)
HistologiX
Nottingham, Nottingham, United Kingdom, Europe
Services
Sample receipt, processing and sectioning for FFPE, frozen and decalcified tissues; routine and specialised stains; custom trimming and blocking for multiple species and medical devices.
Development, optimisation and transfer of chromogenic and fluorescent assays, multiplex assay support, antibody and control tissue sourcing, and study design support.
Brightfield and fluorescence whole-slide scanning, secure digital storage, remote access, and quantitative image analysis including tissue segmentation, cell phenotyping and spatial analyses using AI-driven tools.
GLP TCR studies for therapeutic antibodies and related modalities to evaluate off-target and unexpected on-target binding using human tissue panels and expert pathology reads for regulatory submissions.
Standardisation of collection and shipping protocols, assay validation on human tissue, sample handling SOPs, biopsy kit preparation and pathology review to support clinical trial endpoints.
Processing, assessment and audited GLP pathologist reporting for routine and specialised toxicology studies across multiple species and tissues.
Sample receipt, processing and sectioning for FFPE, frozen and decalcified tissues; routine and specialised stains; custom trimming and blocking for multiple species and medical devices.
Development, optimisation and transfer of chromogenic and fluorescent assays, multiplex assay support, antibody and control tissue sourcing, and study design support.
Brightfield and fluorescence whole-slide scanning, secure digital storage, remote access, and quantitative image analysis including tissue segmentation, cell phenotyping and spatial analyses using AI-driven tools.
GLP TCR studies for therapeutic antibodies and related modalities to evaluate off-target and unexpected on-target binding using human tissue panels and expert pathology reads for regulatory submissions.
Standardisation of collection and shipping protocols, assay validation on human tissue, sample handling SOPs, biopsy kit preparation and pathology review to support clinical trial endpoints.
Processing, assessment and audited GLP pathologist reporting for routine and specialised toxicology studies across multiple species and tissues.
Expertise Areas
- Tissue-based biomarker analysis
- Histology and histopathology
- Immunohistochemistry and immunofluorescence assay development
- Multiplex spatial biology
Key Technologies
- Immunohistochemistry (IHC)
- Immunofluorescence (IF)
- Multiplex immunofluorescence (mIF)
- In situ hybridization (RNA ISH)
News & Updates
Participation at the Bionow Oncology conference; company representatives attending and presenting.
Attendance at the Biomarkers and Precision Medicine conference; company representatives participating.
Announcement that the company has been awarded ISO 9001:2015 certification for its Quality Management System covering tissue-based pre-clinical and clinical contract research activities.
Announcement of the addition of an AI-driven image analysis platform to the digital pathology workflow alongside an existing platform.
Event participation announcement for BioTrinity conference and invitation to meet company representatives.
Whitepaper describing the role of tissue cross-reactivity assays as a screening tool and regulatory requirement for preclinical large-molecule development. Download gated behind a signup form.
Participation at the Bionow Oncology conference; company representatives attending and presenting.
Attendance at the Biomarkers and Precision Medicine conference; company representatives participating.
Announcement that the company has been awarded ISO 9001:2015 certification for its Quality Management System covering tissue-based pre-clinical and clinical contract research activities.
Announcement of the addition of an AI-driven image analysis platform to the digital pathology workflow alongside an existing platform.
Event participation announcement for BioTrinity conference and invitation to meet company representatives.
Whitepaper describing the role of tissue cross-reactivity assays as a screening tool and regulatory requirement for preclinical large-molecule development. Download gated behind a signup form.